Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | PARG | Q86W56 | 1/20 | 0.33 |
| ▸ | IL6 | P05231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19378167 | 0.87 | TLR7 (0.37) | TLR7GABRA1GABRA5ADORA3PARG | |
| SCHEMBL19378204 | 0.85 | TLR7 (0.44) | TLR7ADORA1ADORA3 | |
| SCHEMBL22733691 | 0.84 | ADORA3 (0.45) | TLR7ADORA1ADORA3 | |
| SCHEMBL19378193 | 0.83 | TLR7 (0.43) | TLR7ADORA1ADORA3 | |
| SCHEMBL19378152 | 0.82 | TLR7 (0.43) | TLR7ADORA1 | |
| SCHEMBL19378349 | 0.82 | TYMS (0.44) | TLR7ADORA3 | |
| SCHEMBL19378275 | 0.82 | TLR7 (0.39) | TLR7ADORA1GABRA1GABRA5PARG | |
| SCHEMBL19378119 | 0.79 | TLR7 (0.40) | TLR7ADORA3 | |
| SCHEMBL19378309 | 0.79 | PDE1A (0.39) | ADORA1ADORA3 | |
| SCHEMBL19378189 | 0.78 | PDE4A (0.46) | TLR7ADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | HOFFMANN-LA ROCHE INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275286-A1 | Novel Sulfonimidoylpurinone Compounds and Derivatives for the Treatment and Prophylaxis of Virus Infection | PRSS1, TPMT, SULT1E1 | TLR7 259/4885ADORA1 3185/4885GABRA1 3804/4885 |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | NQO1, UGT1A1, SULT1E1 | TLR7 2425/4885ADORA1 3077/4885GABRA1 4041/4885 |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | STS, SULT1E1, SULT1A1 | TLR7 2510/4885ADORA1 3489/4885GABRA1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.